文献速递神经肿瘤

通过外周血、脑脊液和尿液中游离DNA的液体活检检测儿童脑肿瘤的基因组改变

Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
PubMed 文献 · Neuro Oncol · 2022-01-01

该前瞻性研究纳入258例患者,采集564份标本(257份血液、240份尿液、67份脑脊液),采用超低深度全基因组测序(ULP-WGS)评估拷贝数变异并估计肿瘤分数,同时开发儿童中枢神经系统肿瘤杂交捕获面板进行深度测序。结果显示脑脊液可检测到的DNA最多,但仅在高级别肿瘤的小部分亚组中分子分型可行,多数肿瘤克隆性畸变水平低,液体活检在儿童脑肿瘤中仍面临重大挑战。

要点

  • 脑脊液可检测到的循环肿瘤DNA(ctDNA)最多,但总体水平极低。
  • 仅在高级别肿瘤的小部分亚组中分子分型可行。
  • 多数肿瘤每基因组克隆性畸变水平低,全基因组或靶向测序检测均困难。

核心结论

  • 儿童脑肿瘤患者血液、脑脊液和尿液中ctDNA水平极低,脑脊液可检测到的DNA最多。
  • 仅在高级别肿瘤的小部分亚组中分子分型可行。
  • 多数肿瘤每基因组克隆性畸变水平低,对全基因组或靶向测序检测构成挑战。
  • 从液体活检对儿童脑肿瘤进行基因表征仍存在重大挑战。

研究设计与样本

  • 前瞻性研究,纳入258例患者,采集564份标本(257份血液、240份尿液、67份脑脊液),覆盖所有组织病理学类型。
  • 采用超低深度全基因组测序(ULP-WGS)评估拷贝数变异并估计肿瘤分数。
  • 开发儿童中枢神经系统肿瘤杂交捕获面板,对特定突变和融合进行深度测序。

主要发现

  • ULP-WGS在9/46(20%)脑脊液、3/230(1.3%)血浆和0/153尿液样本中检测到拷贝数改变。
  • 测序面板在3/10(30%)脑脊液、2/74(2.7%)血浆和0/2尿液样本中检测到改变。
  • 仅高级别肿瘤出现阳性结果。
  • 大多数样本可被测序面板发现的体细胞突变不足(中位数1,范围0-39),无法提供足够效力检测大于0.1%的肿瘤分数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 大多数样本可被测序面板发现的体细胞突变不足(中位数1,范围0-39),无法提供足够效力检测大于0.1%的肿瘤分数。
  • 多数肿瘤每基因组克隆性畸变水平低,对全基因组或靶向测序检测构成挑战。
  • 从液体活检对儿童脑肿瘤进行基因表征仍存在重大挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ability to identify genetic alterations in cancers is essential for precision medicine; however, surgical approaches to obtain brain tumor tissue are invasive. Profiling circulating tumor DNA (ctDNA) in liquid biopsies has emerged as a promising approach to avoid invasive procedures. Here, we systematically evaluated the feasibility of profiling pediatric brain tumors using ctDNA obtained from plasma, cerebrospinal fluid (CSF), and urine. METHODS: We prospectively collected 564 specimens (257 blood, 240 urine, and 67 CSF samples) from 258 patients across all histopathologies. We performed ultra-low-pass whole-genome sequencing (ULP-WGS) to assess copy number variations and estimate tumor fraction and developed a pediatric CNS tumor hybrid capture panel for deep sequencing of specific mutations and fusions. RESULTS: ULP-WGS detected copy number alterations in 9/46 (20%) CSF, 3/230 (1.3%) plasma, and 0/153 urine samples. Sequencing detected alterations in 3/10 (30%) CSF, 2/74 (2.7%) plasma, and 0/2 urine samples. The only positive results were in high-grade tumors. However, most samples had insufficient somatic mutations (median 1, range 0-39) discoverable by the sequencing panel to provide sufficient power to detect tumor fractions of greater than 0.1%. CONCLUSIONS: Children with brain tumors harbor very low levels of ctDNA in blood, CSF, and urine, with CSF having the most DNA detectable. Molecular profiling is feasible in a small subset of high-grade tumors. The level of clonal aberrations per genome is low in most of the tumors, posing a challenge for detection using whole-genome or even targeted sequencing methods. Substantial challenges therefore remain to genetically characterize pediatric brain tumors from liquid biopsies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Pagès M, Rotem D, Gydush G, et al. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022. PMID: 34984433. doi:10.1093/neuonc/noab299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。